DISPATCHES FROM INTERPHEX

To QbD or not to QbD? For biologics it's a must says Cook Pharmica expert

By Dan Stanton

- Last updated on GMT

Related tags: Protein

The thorny issue of applying QbD to biopharmaceutical manufacture is a topic of hot debate at Interphex 2014 according to CMO Cook Pharmica.

Recently, progress has been made in the application of quality by design (QbD) to biopharmaceuticals, notably as a result of the US Food and Drug Administration’s (FDA) publication​ of process validation guidelines that integrated ICH principals.

But for biopharmaceutical manufacturers the additional complexity of using QbD can be an issue according to Kumar​ Dhanasekharan, director of process development for biologics at Cook Pharmica.

It is a bit more complicated [to apply QbD to biopharmaceuticals] than it is to small molecules simply because the analytical methods we use for biologics are not able to characterise the molecule to the same extent.”

He explained that while for small molecules analytical methods can determine the structure and its entire makeup from an efficacy and safety perspective, this is just not possible for biologics.

For a biologics the QbD depends upon the analytical methods we have. Obviously we can look at the amino acid sequence, the secondary and tertiary structure of the protein but you really never fully characterise the molecule.”

Related news

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars